bioRxivBiochemistry
Covalent targeting as a common mechanism for inhibiting NLRP3 inflammasome assembly.
C. Stanton, J. Sun, K. Nutsch, J. D. Rosarda, T. Nguyen, C. Li-Ma, S. Kutseikin, E. Saez, J. R. Teijaro, L. Wiseman, M. J. Bollong
Abstract
The NLRP3 inflammasome is a cytosolic protein complex important for the regulation and secretion of inflammatory cytokines including IL-1{beta} and IL-18. Aberrant overactivation of NLRP3 is implicated in numerous inflammatory disorders. However, the activation and regulation of NLRP3 inflammasome signaling remains poorly understood, limiting our ability to develop pharmacologic approaches to target this important inflammatory complex. Here, we developed and implemented a high-throughput screen to identify compounds that inhibit inflammasome assembly and activity. From this screen we identify and profile inflammasome inhibition of 20 new covalent compounds across 9 different chemical scaffolds, as well as many known inflammasome covalent inhibitors. Intriguingly, our results indicate that NLRP3 possesses numerous reactive cysteines on multiple domains whose covalent targeting blocks activation of this inflammatory complex. Specifically, focusing on compound VLX1570, which possesses multiple electrophilic moieties, we demonstrate that this compound allows covalent, intermolecular crosslinking of NLRP3 cysteines to inhibit inflammasome assembly. Our results, along with the recent identification of numerous covalent molecules that inhibit NLRP3 inflammasome activation, suggests that NLRP3 serves as a cellular electrophile sensor important for coordinating inflammatory signaling in response to redox stress. Further, our results support the potential for covalent cysteine modification of NLRP3 for regulating inflammasome activation and activity.
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Inhibition of NLRP3 by a CNS-penetrating indazole scaffold
Jane Torp, Dominic Ferber, … Matthias Geyer·bioRxiv·Jul 1, 2025
- Mapping the reactive cysteine landscape of the NOD-like receptor pyrin domain-containing 3 protein
Bjoern K Ziehr, Bruno C Amaral, … Justin A MacDonald·bioRxiv·Nov 9, 2026
- Discovery of a Potent and Selective Inhibitor of Human NLRP3 with a Novel Binding Modality and Mechanism of Action
Kevin Wilhelmsen, Aditi Deshpande, … Rebecca C. Coll·The Journal of Experimental MedicinePeer-reviewed·Jul 24, 2025
- FDA-approved drug library screen identifies antidepressants, antimicrobials, anti-COPD, and anti-CVD agents as blockers of NLRP3 inflammasome and sepsis in a sex-dependent manner.
Kara Timinski, Ashutosh Prince, … Kailash Gulshan·bioRxiv·Jul 29, 2026
- Minoxidil hydrochloride impedes NLRP3 inflammasome activation via upregulation of AMPK-mediated autophagy
Sukhleen Kaur, Mehboob Ali, … Ajay Kumar·bioRxiv·Oct 16, 2026
- Cryo-EM structure of the NLRP3 decamer bound to the cytokine release inhibitory drug CRID3
I. V. Hochheiser, M. Pilsl, … M. Geyer·bioRxiv·Jul 22, 2021